Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 9;8(8):863.
doi: 10.3390/cells8080863.

Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics

Artemiy S Silantyev  1   2 , Luca Falzone  3 , Massimo Libra  3   4 , Olga I Gurina  5 , Karina Sh Kardashova  5 , Taxiarchis K Nikolouzakis  6 , Alexander E Nosyrev  2   7 , Christopher W Sutton  8 , Panayiotis D. Mitsias  9   10 , Aristides Tsatsakis  11   12
Affiliations
Review

Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics

Artemiy S Silantyev et al. Cells. .

Abstract

Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous system. Due to the absence of effective pharmacological and surgical treatments, the identification of early diagnostic and prognostic biomarkers is of key importance to improve the survival rate of patients and to develop new personalized treatments. On these bases, the aim of this review article is to summarize the current knowledge regarding the application of molecular biology and proteomics techniques for the identification of novel biomarkers through the analysis of different biological samples obtained from glioblastoma patients, including DNA, microRNAs, proteins, small molecules, circulating tumor cells, extracellular vesicles, etc. Both benefits and pitfalls of molecular biology and proteomics analyses are discussed, including the different mass spectrometry-based analytical techniques, highlighting how these investigation strategies are powerful tools to study the biology of glioblastoma, as well as to develop advanced methods for the management of this pathology.

Keywords: DNA; biomarkers; mass spectrometry; metabolomics; miRNAs; proteins; proteomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Molecular alterations responsible for glioblastoma carcinogenesis [66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85].
See this image and copyright information in PMC

References

    1. Westermark B. Glioblastoma—A moving target. Ups. J. Med. Sci. 2012;117:251–256. doi: 10.3109/03009734.2012.676574. - DOI - PMC - PubMed
    1. Salcman M. Malignant glioma management. Neurosurg. Clin. N. Am. 1990;1:49–63. doi: 10.1016/S1042-3680(18)30823-4. - DOI - PubMed
    1. Lombardi G., Corona G., Bellu L., Della Puppa A., Pambuku A., Fiduccia P., Bertorelle R., Gardiman M.P., D’Avella D., Toffoli G., et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. Oncologist. 2015;20:562–567. doi: 10.1634/theoncologist.2014-0266. - DOI - PMC - PubMed
    1. Mallick S., Benson R., Hakim A., Rath G.K. Management of glioblastoma after recurrence: A changing paradigm. Egypt. Natl. Cancer Inst. 2016;28:199–210. doi: 10.1016/j.jnci.2016.07.001. - DOI - PubMed
    1. Liu B., Dong H., Lin X., Yang X., Yue X., Yang J., Li Y., Wu L., Zhu X., Zhang S., et al. RND3 promotes Snail 1 protein degradation and inhibits glioblastoma cell migration and invasion. Oncotarget. 2016;7:82411–82423. doi: 10.18632/oncotarget.12396. - DOI - PMC - PubMed

Publication types

LinkOut - more resources